Results from the SOUL Trial: The Diabetologists' Perspective
Show notes
Watch the full interview on YouTube to learn more about the SOUL trial, a landmark study presented at the EASD 2025 Annual Meeting investigating cardiovascular outcomes with an oral GLP-1 receptor agonist.
In this episode, Dr Rodica Busui (Oregon Health & Science University-OHSU, Oregon, USA) explains why the SOUL trial represents a significant milestone in diabetes and cardiovascular care. She discusses how the oral formulation achieved a 14% reduction in major adverse cardiovascular events (MACE), matching results previously observed with injectable GLP-1 therapies.
Dr Busui also explores:
- The relevance of the findings for people with type 2 diabetes at high cardiovascular risk
- New insights into heart failure phenotypes, particularly HFpEF, and their growing prevalence
- Why oral GLP-1 therapies may help expand access, especially for older adults or those unable to manage injections
- Key safety observations regarding combined use with SGLT2 inhibitors, which was seen in nearly half of trial participants
Read the full publication for a deeper dive into the SOUL trial data once available online.
Stay tuned for more expert insights and breakthrough conversations from EASD TV. To learn more about our expert speaker:
New comment